OrbusNeich Medical Group (6929) Fair Value & Analysis
Healthcare · HK · Market cap HK$3.2B
Fair value as of: Aug 6, 2026
From 25 valuation models · updated 5 days ago
Fair value updated Aug 6, 2026, revised from HK$0.8500 to HK$0.8300 (−2.4%) since Jul 2, 2026. Share price +2.5% over the past month.
A solid business, but screening 78% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$1.23). The favourable scenario is already priced in.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (HK$0.5500 to HK$1.23) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 6, 2026.
How to read this chart
44‑month range HK$2.61 – HK$12.53 · fair‑value band HK$0.5500 – HK$1.23 · the HK$3.76 price screens above the HK$0.8300 fair value. Dashed = 300-day average. As of Aug 6, 2026.
Analysis
OrbusNeich Medical Group (6929) currently trades at HK$3.76, while our model-based Fair Value estimate is HK$0.8300, implying the stock looks roughly 77.9% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, OrbusNeich Medical Group generated revenue of HK$180M at a net margin of 23.2%. Revenue grew 13.8% year over year. It earns a return on equity of 10.4%. The balance sheet holds a net cash position of HK$215M. Fundamentals as of Aug 6, 2026
Our scenario range runs from HK$0.5500 (bear case) to HK$1.23 (bull case); at HK$3.76, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -78%, 6929 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Growth Earnings (HK$0.9600) versus Growth DCF (HK$0.2900). Highest evidence: Growth DCF (80).
Notify me when 6929 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 6, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 44
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
OrbusNeich Medical Group Holdings Limited, an investment holding company, engages in the manufacture, trading, sale, and marketing of medical devices/instruments for the treatment of coronary and peripheral vascular diseases.
Full company description
OrbusNeich Medical Group Holdings Limited, an investment holding company, engages in the manufacture, trading, sale, and marketing of medical devices/instruments for the treatment of coronary and peripheral vascular diseases. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, drug-coated balloons and stents for lesion therapy, non-compliant balloons for post-dilatation, and specialty catheters, as well as microcatheters, guide catheter extension, dual therapy, and drug eluting stents. Its product portfolio covers various treatment processes in percutaneous coronary intervention and percutaneous transluminal angioplasty procedures. It operates in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People's Republic of China, the United States, and internationally. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong. OrbusNeich Medical Group Holdings Limited is a subsidiary of Harmony Tree Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
OrbusNeich Medical Group reported revenue of HK$180M in FY2025 versus HK$116M in FY2021, a compound +11.6%/yr. Reported net income was HK$41.9M in FY2025.
6929 screens 78% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare OrbusNeich Medical Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is OrbusNeich Medical Group (6929) overvalued or undervalued?
What is the fair value of 6929?
What is the quality score of 6929?
What is the revenue of OrbusNeich Medical Group (6929)?
What is the net profit margin of 6929?
Does OrbusNeich Medical Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track OrbusNeich Medical Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.